Skip to content
BioRegenis — home

From biomarker to product

We develop biotechnology that keeps people healthy and well

Biochips for individual analysis, and formulations built on the data of one person.

Go to the pipelineInvestor relations

Average maturity 44.3%

Our work

BioRegenis works on an idea that is simple to state and hard to deliver: measure what happens inside one person's body and use that data to build the right product for them. Not a product for everyone, adapted to someone; a path that starts from the measurement.

That takes three things we keep together: the ability to read individual biomarkers, the computational tools to interpret them, and the formulation and regulatory competence to turn that interpretation into a product that can legally reach the market.

Where we stand

Six programmes, from basic research to a product on the market. For each one we publish the real state of progress, the next milestone and the date of the last update.

BioChip Skin

Digital health and biosensors

28%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

BioRegenis PV

Drug safety software

61%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

CareGamers

Personal health and performance

95%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

PT-LB

Dermocosmetic research

50%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

BioRegenis Biomolecular Gen

Computational biotechnology

17%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

Robotics

Devices and automation

15%

  1. TRL 1
  2. TRL 2
  3. TRL 3
  4. TRL 4
  5. TRL 5
  6. TRL 6
  7. TRL 7
  8. TRL 8
  9. TRL 9

The TRL 1–9 scale measures the technological maturity of a programme: the percentage marks its position along that scale, not its distance from market entry. Programme status updated August 2026.

Full detail

Three ways in

  • The pipeline

    Six programmes, from basic research to a product on the market, each with its real state, its next milestone and the date of the last update.

    Go to the Pipeline

  • How we innovate

    We start from computational analysis, not from the finished product. Molecules, mechanisms of action, ADME and toxicology are assessed before a formula exists, to cut the time and the cost of mistakes.

    Go to Innovation

  • The method

    We describe what we are studying, not what we hope to obtain. It is the criterion every piece of content on this site is written by.

    Go to the Mission

Investor relations

BioRegenis is considering investors to support the next phases of development.

Investor section